posted on 2021-03-16, 04:45authored byKyoung Im Cho, Dong Woon Jeon, Hyo Seung Ahn, Dong Kyu Jin, Hyun Sang Lee, Jong-Young Lee, Hong-Seok Lim, Athanasios J. Manolis, Seung-Woon Rha, Sang Won Park
Additional file 1: Table S1. Adverse events (AEs) with an incidence of ≥0.5% in at least one of the subgroups in the safety population in the BENEFIT-KOREA study. Table S2. Adverse drug reactions (ADRs) in the safety population in BENEFIT-KOREA study.